TuHURA Biosciences (NASDAQ:HURA) Stock Breaks Below 200-Day Moving Average – Here’s What Happened

TuHURA Biosciences, Inc. (NASDAQ:HURA)’s stock price passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $1.96 and traded as low as $1.85. TuHURA Biosciences shares last traded at $1.93, with a volume of 519,359 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of TuHURA Biosciences in a research note on Tuesday. Citizens Jmp reiterated a “market outperform” rating and set a $9.00 price target on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, October 15th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

TuHURA Biosciences Stock Down 6.3%

The company has a market capitalization of $123.00 million, a PE ratio of -3.57 and a beta of -0.21. The company’s fifty day moving average is $2.02 and its 200-day moving average is $1.96. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.18 and a current ratio of 0.18.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. As a group, analysts predict that TuHURA Biosciences, Inc. will post -0.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Squarepoint Ops LLC bought a new position in TuHURA Biosciences in the 2nd quarter worth $81,000. HighTower Advisors LLC raised its holdings in TuHURA Biosciences by 42.5% during the second quarter. HighTower Advisors LLC now owns 30,151 shares of the company’s stock valued at $71,000 after acquiring an additional 8,999 shares during the period. Two Sigma Securities LLC bought a new stake in TuHURA Biosciences during the second quarter valued at about $33,000. Hsbc Holdings PLC bought a new stake in TuHURA Biosciences during the second quarter valued at about $69,000. Finally, Jefferies Financial Group Inc. purchased a new position in shares of TuHURA Biosciences in the second quarter valued at about $98,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.